title: Hormonal manipulation of lower urinary tract symptoms secondary to benign prostatic obstruction.
abstract: Although the etiology of lower urinary tract symptoms (LUTS) is often multifactorial, a significant proportion of men over the age of 50 suffer from benign prostatic obstruction (BPO) secondary to benign prostatic hyperplasia. Prostate, being an androgen responsive organ is dependent on the male sex hormone, testosterone, for growth. Thus, treatment strategies that manipulate the levels of circulating hormones that influence the level of testosterone and/or prostatic growth represent an important potential option for patients suffering with troublesome LUTS due to BPO. Despite this, the only hormonal treatment that is currently used in daily clinical practice is the 5-alpha reductase inhibitor. In this article, we review the current evidence on the use of the 5-alpha reductase inhibitors finasteride and dutasteride. We also discuss new emerging hormonal manipulation strategies for patients with LUTS secondary to BPO.
authors.affiliation: Department of Urology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
authors.forename: Adita
authors.initials: A
authors.lastname: Raja
authors.affiliation: Department of Uro-Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hori
authors.affiliation: Department of Urology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
authors.forename: James N
authors.initials: JN
authors.lastname: Armitage
keywords: 5-alpha reductase inhibitors; benign prostatic hypertrophy; benign prostatic obstruction; gonadotropin hormone releasing hormone; growth hormone releasing hormone; lower urinary tract symptoms; luteinizing hormone releasing hormone
references.citation: Differentiation. 2011 Nov-Dec;82(4-5):184-99
references.pmid: 21620560
references.citation: Clin Endocrinol (Oxf). 1994 Aug;41(2):139-47
references.pmid: 7522999
references.citation: Prostate. 2013 Jun;73(8):873-83
references.pmid: 23280565
references.citation: Eur Urol. 2013 Jul;64(1):118-40
references.pmid: 23541338
references.citation: N Engl J Med. 2003 Dec 18;349(25):2387-98
references.pmid: 14681504
references.citation: J Urol. 1992 Nov;148(5):1549-57; discussion 1564
references.pmid: 1279218
references.citation: BMJ. 1996 Mar 23;312(7033):767-70
references.pmid: 8605468
references.citation: Prostate. 2010 Jul 1;70(10):1087-93
references.pmid: 20232355
references.citation: Br J Pharmacol. 2011 Jul;163(5):891-907
references.pmid: 21410684
references.citation: Urol Clin North Am. 1990 Aug;17(3):661-70
references.pmid: 1695786
references.citation: BJU Int. 2011 Aug;108(3):388-94
references.pmid: 21631695
references.citation: Curr Opin Urol. 2012 Jan;22(1):7-15
references.pmid: 22080875
references.citation: Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3755-60
references.pmid: 21321192
references.citation: Prostate. 2011 May 15;71(7):736-47
references.pmid: 20945403
references.citation: Front Biosci. 2007 Sep 01;12:4957-71
references.pmid: 17569623
references.citation: Int J Urol. 2008 Mar;15(3):193-9
references.pmid: 18304211
references.citation: J Clin Endocrinol Metab. 1998 Nov;83(11):3826-31
references.pmid: 9814453
references.citation: Rev Urol. 2005;7 Suppl 6:S3-S13
references.pmid: 16986027
references.citation: Mayo Clin Proc. 1993 Jul;68(7):670-9
references.pmid: 7688840
references.citation: J Urol. 2011 Apr;185(4):1369-73
references.pmid: 21334655
references.citation: BJU Int. 2010 Nov;106(9):1382-8
references.pmid: 20151966
references.citation: Adv Urol. 2012;2012:530121
references.pmid: 22235201
references.citation: Prostate. 1994;24(2):84-92
references.pmid: 7508623
references.citation: Prostate. 1993;22(1):31-7
references.pmid: 7678930
references.citation: Prostate. 2011 Apr;71(5):445-52
references.pmid: 20859992
references.citation: Eur Urol. 2010 Jan;57(1):123-31
references.pmid: 19825505
references.citation: N Engl J Med. 1998 Feb 26;338(9):557-63
references.pmid: 9475762